Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation-Reference-Cited by-同舟云学术

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation

Published:2017-08-14 Issue:9 Volume:23 Page:1055-1062
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Zhang Pingzhao,Wang Dejie,Zhao Yu,Ren Shancheng,Gao Kun,Ye Zhenqing,Wang Shangqian,Pan Chun-Wu,Zhu Yasheng,Yan Yuqian,Yang Yinhui,Wu Di,He Yundong,Zhang Jun,Lu Daru,Liu Xiuping,Yu Long,Zhao Shimin,Li Yao,Lin Dong,Wang Yuzhuo,Wang Liguo^ORCID,Chen Yu,Sun Yinghao,Wang Chenji,Huang Haojie

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4379.pdf

Reference50 articles.

1. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

2. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010).

3. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).

4. Dawson, M.A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).

5. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy;Bioorganic & Medicinal Chemistry;2024-10

2. Vascular Calcification Is Accelerated by Hyponatremia and Low Osmolality;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-09

3. Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis;Cell Reports;2024-07

4. FBXO28 promotes the malignancy of non-small cell lung cancer through ubiquitination-mediated activation of BRD4;2024-04-19

5. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review);Oncology Reports;2024-04-12